Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice: A key role of transforming growth factor-β1

Sebastiano Alfio Torrisi, Federica Geraci, Maria Rosaria Tropea, Margherita Grasso, Giuseppe Caruso, Annamaria Fidilio, Nicolò Musso, Giulia Sanfilippo, Fabio Tascedda, Agostino Palmeri, Salvatore Salomone, Filippo Drago, Daniela Puzzo, Gian Marco Leggio, Filippo Caraci

Research output: Contribution to journalArticle

Abstract

Depression is a risk factor for the development of Alzheimer's disease (AD), and the presence of depressive symptoms significantly increases the conversion of mild cognitive impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD, and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently being studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ1-42) oligomers in 2-month-old C57BL/6 mice. Starting from 7 days before Aβ injection, fluoxetine (10 mg/kg) and vortioxetine (5 and 10 mg/kg) were intraperitoneally injected daily for 24 days. Chronic treatment with fluoxetine and vortioxetine (both at the dose of 10 mg/kg) was able to rescue the loss of memory assessed 14 days after Aβ injection by the passive avoidance task and the object recognition test. Both antidepressants reversed the increase in immobility time detected 19 days after Aβ injection by forced swim test. Vortioxetine exerted significant antidepressant effects also at the dose of 5 mg/kg. A significant deficit of transforming growth factor-β1 (TGF-β1), paralleling memory deficits and depressive-like phenotype, was found in the hippocampus of Aβ-injected mice in combination with a significant reduction of the synaptic proteins synaptophysin and PSD-95. Fluoxetine and vortioxetine completely rescued hippocampal TGF-β1 levels in Aβ-injected mice as well as synaptophysin and PSD-95 levels. This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribution of TGF-β1.

Original languageEnglish
Article number693
JournalFrontiers in Pharmacology
Volume10
Issue numberJUN
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Fluoxetine
Memory Disorders
Transforming Growth Factors
Amyloid
Antidepressive Agents
Alzheimer Disease
Phenotype
Synaptophysin
Injections
Serotonin Uptake Inhibitors
Depression
Aptitude
Inbred C57BL Mouse
vortioxetine
Hippocampus
Therapeutics
Animal Models
Proteins

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Antidepressants
  • Depression
  • Fluoxetine
  • Memory
  • TGF-β1
  • Vortioxetine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice : A key role of transforming growth factor-β1. / Torrisi, Sebastiano Alfio; Geraci, Federica; Tropea, Maria Rosaria; Grasso, Margherita; Caruso, Giuseppe; Fidilio, Annamaria; Musso, Nicolò; Sanfilippo, Giulia; Tascedda, Fabio; Palmeri, Agostino; Salomone, Salvatore; Drago, Filippo; Puzzo, Daniela; Leggio, Gian Marco; Caraci, Filippo.

In: Frontiers in Pharmacology, Vol. 10, No. JUN, 693, 01.01.2019.

Research output: Contribution to journalArticle

Torrisi, SA, Geraci, F, Tropea, MR, Grasso, M, Caruso, G, Fidilio, A, Musso, N, Sanfilippo, G, Tascedda, F, Palmeri, A, Salomone, S, Drago, F, Puzzo, D, Leggio, GM & Caraci, F 2019, 'Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice: A key role of transforming growth factor-β1', Frontiers in Pharmacology, vol. 10, no. JUN, 693. https://doi.org/10.3389/fphar.2019.00693
Torrisi, Sebastiano Alfio ; Geraci, Federica ; Tropea, Maria Rosaria ; Grasso, Margherita ; Caruso, Giuseppe ; Fidilio, Annamaria ; Musso, Nicolò ; Sanfilippo, Giulia ; Tascedda, Fabio ; Palmeri, Agostino ; Salomone, Salvatore ; Drago, Filippo ; Puzzo, Daniela ; Leggio, Gian Marco ; Caraci, Filippo. / Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice : A key role of transforming growth factor-β1. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. JUN.
@article{679662bcd2fd4803a445aae98fb4bfaa,
title = "Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice: A key role of transforming growth factor-β1",
abstract = "Depression is a risk factor for the development of Alzheimer's disease (AD), and the presence of depressive symptoms significantly increases the conversion of mild cognitive impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD, and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently being studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ1-42) oligomers in 2-month-old C57BL/6 mice. Starting from 7 days before Aβ injection, fluoxetine (10 mg/kg) and vortioxetine (5 and 10 mg/kg) were intraperitoneally injected daily for 24 days. Chronic treatment with fluoxetine and vortioxetine (both at the dose of 10 mg/kg) was able to rescue the loss of memory assessed 14 days after Aβ injection by the passive avoidance task and the object recognition test. Both antidepressants reversed the increase in immobility time detected 19 days after Aβ injection by forced swim test. Vortioxetine exerted significant antidepressant effects also at the dose of 5 mg/kg. A significant deficit of transforming growth factor-β1 (TGF-β1), paralleling memory deficits and depressive-like phenotype, was found in the hippocampus of Aβ-injected mice in combination with a significant reduction of the synaptic proteins synaptophysin and PSD-95. Fluoxetine and vortioxetine completely rescued hippocampal TGF-β1 levels in Aβ-injected mice as well as synaptophysin and PSD-95 levels. This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribution of TGF-β1.",
keywords = "Alzheimer's disease, Amyloid-β, Antidepressants, Depression, Fluoxetine, Memory, TGF-β1, Vortioxetine",
author = "Torrisi, {Sebastiano Alfio} and Federica Geraci and Tropea, {Maria Rosaria} and Margherita Grasso and Giuseppe Caruso and Annamaria Fidilio and Nicol{\`o} Musso and Giulia Sanfilippo and Fabio Tascedda and Agostino Palmeri and Salvatore Salomone and Filippo Drago and Daniela Puzzo and Leggio, {Gian Marco} and Filippo Caraci",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00693",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "JUN",

}

TY - JOUR

T1 - Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice

T2 - A key role of transforming growth factor-β1

AU - Torrisi, Sebastiano Alfio

AU - Geraci, Federica

AU - Tropea, Maria Rosaria

AU - Grasso, Margherita

AU - Caruso, Giuseppe

AU - Fidilio, Annamaria

AU - Musso, Nicolò

AU - Sanfilippo, Giulia

AU - Tascedda, Fabio

AU - Palmeri, Agostino

AU - Salomone, Salvatore

AU - Drago, Filippo

AU - Puzzo, Daniela

AU - Leggio, Gian Marco

AU - Caraci, Filippo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Depression is a risk factor for the development of Alzheimer's disease (AD), and the presence of depressive symptoms significantly increases the conversion of mild cognitive impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD, and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently being studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ1-42) oligomers in 2-month-old C57BL/6 mice. Starting from 7 days before Aβ injection, fluoxetine (10 mg/kg) and vortioxetine (5 and 10 mg/kg) were intraperitoneally injected daily for 24 days. Chronic treatment with fluoxetine and vortioxetine (both at the dose of 10 mg/kg) was able to rescue the loss of memory assessed 14 days after Aβ injection by the passive avoidance task and the object recognition test. Both antidepressants reversed the increase in immobility time detected 19 days after Aβ injection by forced swim test. Vortioxetine exerted significant antidepressant effects also at the dose of 5 mg/kg. A significant deficit of transforming growth factor-β1 (TGF-β1), paralleling memory deficits and depressive-like phenotype, was found in the hippocampus of Aβ-injected mice in combination with a significant reduction of the synaptic proteins synaptophysin and PSD-95. Fluoxetine and vortioxetine completely rescued hippocampal TGF-β1 levels in Aβ-injected mice as well as synaptophysin and PSD-95 levels. This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribution of TGF-β1.

AB - Depression is a risk factor for the development of Alzheimer's disease (AD), and the presence of depressive symptoms significantly increases the conversion of mild cognitive impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD, and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently being studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ1-42) oligomers in 2-month-old C57BL/6 mice. Starting from 7 days before Aβ injection, fluoxetine (10 mg/kg) and vortioxetine (5 and 10 mg/kg) were intraperitoneally injected daily for 24 days. Chronic treatment with fluoxetine and vortioxetine (both at the dose of 10 mg/kg) was able to rescue the loss of memory assessed 14 days after Aβ injection by the passive avoidance task and the object recognition test. Both antidepressants reversed the increase in immobility time detected 19 days after Aβ injection by forced swim test. Vortioxetine exerted significant antidepressant effects also at the dose of 5 mg/kg. A significant deficit of transforming growth factor-β1 (TGF-β1), paralleling memory deficits and depressive-like phenotype, was found in the hippocampus of Aβ-injected mice in combination with a significant reduction of the synaptic proteins synaptophysin and PSD-95. Fluoxetine and vortioxetine completely rescued hippocampal TGF-β1 levels in Aβ-injected mice as well as synaptophysin and PSD-95 levels. This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribution of TGF-β1.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Antidepressants

KW - Depression

KW - Fluoxetine

KW - Memory

KW - TGF-β1

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=85069478745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069478745&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00693

DO - 10.3389/fphar.2019.00693

M3 - Article

AN - SCOPUS:85069478745

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUN

M1 - 693

ER -